Elisabetta Valoti

List of Publications by Year
in descending order

19 papers	1,308 citations	840776 11 h-index	839539 18 g-index
22 all docs	22 docs citations	22 times ranked	1421 citing authors

#	Article	IF	Citations
1	CFH and CFHR Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Frontiers in Genetics, 2021, 12, 670727.	2.3	11
2	Molecular Studies and an ex vivo Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 Variant. Frontiers in Medicine, 2020, 7, 579418.	2.6	8
3	More about Factor H Autoantibodies in Membranous Nephropathy. New England Journal of Medicine, 2019, 381, 1590-1592.	27.0	8
4	Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. Frontiers in Genetics, 2019, 10, 681.	2.3	11
5	Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS. Frontiers in Immunology, 2019, 10, 853.	4.8	31
6	An ExÂVivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. American Journal of Kidney Diseases, 2019, 74, 56-72.	1.9	71
7	Hemolytic Uremic Syndrome in an Infant with Primary Hyperoxaluria Type II: An Unreported Clinical Association. Nephron, 2019, 142, 264-270.	1.8	2
8	Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complexâ€“Mediated Membranoproliferative GN. Journal of the American Society of Nephrology: JASN, 2018, 29, 283-294.	6.1	89
9	Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN. Frontiers in Immunology, 2018, 9, 2329.	4.8	37
10	Unravelling the pathophysiology of C3G/IC-MPGN and how to predict disease progression and orient therapies. Molecular Immunology, 2017, 89, 178.	2.2	0
11	Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Molecular Immunology, 2016, 71, 131-142.	2.2	126
12	Association ofCFHR1homozygous deletion with acute myelogenous leukemia in the European population. Leukemia and Lymphoma, 2016, 57, 1234-1237.	1.3	5
13	Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood, 2015, 125, 2359-2369.	1.4	112
14	Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1011-1019.	4.5	47
15	A Novel Atypical Hemolytic Uremic Syndromeâ€“Associated Hybrid CFHR1/CFH Gene Encoding a Fusion Protein That Antagonizes Factor Hâ€“Dependent Complement Regulation. Journal of the American Society of Nephrology: JASN, 2015, 26, 209-219.	6.1	89
16	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood, 2014, 124, 1715-1726.	1.4	288
17	Combined Complement Gene Mutations in Atypical Hemolytic Uremic Syndrome Influence Clinical Phenotype. Journal of the American Society of Nephrology: JASN, 2013, 24, 475-486.	6.1	308
18	Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrology Dialysis Transplantation, 2013, 28, 2246-2259.	0.7	59

#	Article	IF	Citations
19	Posttransplant recurrence of atypical hemolytic uremic syndrome. Journal of Nephrology, 2012, 25, 911-917.	2.0	6